Evotec SE is a Germany-based biotechnology company specializing in drug discovery alliance and development partnerships. Headquartered in Hamburg, the company collaborates with pharmaceutical and biotechnology firms to deliver integrated solutions across the drug discovery and development continuum. Its offerings span from target identification and validation to lead optimization, preclinical development and manufacturing support.
The company’s platform combines expertise in assay development, high-throughput screening, medicinal chemistry, in vivo pharmacology and safety assessment. Evotec operates multiple research sites across Europe, North America and Asia, leveraging proprietary technologies and a multidisciplinary team to advance programs in areas such as neuroscience, oncology, metabolic and infectious diseases.
Founded in 1993 following the consolidation of various German research institutions, Evotec has grown through strategic acquisitions and collaborations. The company went public on the Frankfurt Stock Exchange in 1999 and established an American depositary receipt program under the ticker EVTCY to broaden its investor base.
Under the leadership of Chief Executive Officer Werner Lanthaler, Evotec maintains a global footprint with key facilities in Germany, the United Kingdom, France, Switzerland and the United States. Its partnership model is built on long-term alliances, milestone-driven collaborations and risk-sharing arrangements aimed at accelerating the delivery of novel therapeutic candidates.
AI Generated. May Contain Errors.
